Phase 2 N=12 Cold Challenge With C21 in RP
Raynaud Phenomenon · Systemic Sclerosis
Primary: Area Under the Curve for Rewarming of Each Finger After Cold Challenge (AUC) as Measured by Thermography — 19558.43; 20045.96 C*sec — p==0.3801
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=8 Cannabidiol Use to Reduce Cravings in Individuals With Opioid Use Disorder on Buprenorphine
Opioid-use Disorder
Primary: Change in Cue-induced Cravings and Anxiety After 3 Days of Cannabidiol Administration — 3.2; 0.4 score on a scale
Phase 2 N=50 Phase II Study of Adenovirus/PSA Vaccine in Men With Recurrent Prostate Cancer After Local Therapy APP21
Recurrent Prostate Cancer
Primary: Number of Participants Who Develop a Strong or Modest Anti-PSA Immune Response — 12; 14; 6; 3 participants
Phase 2 N=48 Mitomycin C in Patients With Incurable p16 Positive Oropharyngeal and p16 Negative Head and Neck Squamous Cell Carcinoma (HNSCC) Resistant to Standard Therapies
Squamous Cell Carcinoma of the Head and Neck · Squamous Cell Carcinoma, Head and Neck
Primary: Tumor Response Rate (TRR) — 3; 0 Participants
Phase 2 N=241 Optimization of Spinal Manipulative Therapy Protocols
Low Back Pain
Primary: Spinal Stiffness — 6.20; 6.28; 6.10; 6.07 N/mm — p=0.025
Phase 2 N=217 The Use PUL-042 to Reduce the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2
COVID-19
Primary: Severity of COVID-19: Evaluation of the Severity of COVID-19 as Measured by the Maximum Difference From the Baseline Value in the OSCI Within 28 Days From the Start of…
Phase 2 N=457 A Study of GSK3228836 in Participants With Chronic Hepatitis B (CHB)
Hepatitis B
Primary: Number of Participants Achieving Sustained Virologic Response (SVR) — 6; 6; 2; 0 Participants
Phase 2 N=167 Efficacy and Safety of ETX-018810 for the Treatment of Diabetic Peripheral Neuropathic Pain
Diabetic Peripheral Neuropathic Pain · Diabetic Peripheral Neuropathy
Primary: Change From Baseline to Week 4 in the Weekly Average of the Daily Pain Score as Derived From the Subject's Responses on the Pain Intensity Numerical Rating Scale…
Phase 2 N=227 A Confirmatory Safety and Efficacy Study of BBI-4000 in Subjects With Axillary Hyperhidrosis
Hyperhidrosis
Primary: Change of Hyperhidrosis Disease Severity Measure-Axillary (HDSM-Ax) Score From Baseline to End of Therapy — -1.30; -2.02; -2.09; -2.10 score on a scale
Phase 2 N=13 Nelipepimut-S Plus GM-CSF Vaccine Therapy in Treating Patients With Breast Cancer
Breast Ductal Carcinoma In Situ
Primary: Mean Percent of Nelipepimut-S-specific Cytotoxic T Lymphocyte Response (E75) — 0.09; 0.02 percent of cytotoxic T lymphocytes — p=0.71
Phase 2 N=42 Safety and Tolerability of RGX-314 (Investigational Product) Gene Therapy for Neovascular AMD Trial
Neovascular Age-related Macular Degeneration · Wet Age-related Macular Degeneration
Primary: Safety (Participants With Ocular and Non-ocular AEs (Adverse Events) and SAEs (Serious Adverse Events)) — 6; 6; 6; 12 Participants
Phase 2 N=2 BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer
Metastatic Pancreatic Adenocarcinoma · Recurrent Pancreatic Carcinoma · Stage III Pancreatic Cancer
Primary: Median Overall Survival (OS) — 0.934 years
Phase 2 N=264 Study to Evaluate BIIB059 (Litifilimab) in Cutaneous Lupus Erythematosus (CLE) With or Without Systemic Lupus Erythematosus (SLE)
Systemic Lupus Erythematosus · Active Cutaneous Lupus Erythematosus
Primary: Part A: Change From Baseline in Active Joint Count (28-joint Assessment) to Week 24 — -12.7; -9.0; -13.0; -14.5 joints — p=0.037
Phase 2 N=69 Atorvastatin as GVHD Prophylaxis for Allogeneic Hematopoietic Cell Transplantation
Graft vs Host Disease
Primary: Matched Related Transplants Who Develop Grade II-IV Acute Graft Versus Host Disease (GVHD). — 3 Participants
Phase 2 N=14 Walnut Oral Immunotherapy for Tree Nut Allergy
Tree Nut Allergy
Primary: Effectiveness of Walnut OIT on Clinical Desensitization to Test Tree Nut as Measured by Change in Cumulative Tolerated Dose From Baseline to Week 38 at Oral Food…